Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma
2006; Karger Publishers; Volume: 70; Issue: 4 Linguagem: Inglês
10.1159/000096249
ISSN1423-0232
AutoresNikolaos Androulakis, Gerasimos Aravantinos, Kostas Syrigos, Aris Polyzos, Nikolaos Ziras, Evangelos Tselepatiotis, George Samonis, Nikolaos Kentepozidis, Stylianos Giassas, Lambros Vamvakas, Vassilis Georgoulias,
Tópico(s)Gallbladder and Bile Duct Disorders
Resumo<i>Background:</i> A multicenter phase II study was conducted in order to evaluate the efficacy and safety of oxaliplatin as first-line treatment of patients with locally advanced or metastatic carcinoma of the biliary tract. <i>Patients and Methods:</i> Twenty-nine chemo-naïve patients with locally advanced or metastatic biliary tract carcinoma received oxaliplatin 130 mg/m<sup>2</sup> i.v. every 21 days. Patients were treated until tumor progression or unacceptable toxicity. <i>Results:</i> An objective response (3 complete responses, 3 partial responses) was achieved in 6 patients (20.6%, 95% CI 5.95–35.4). Disease control (complete response, partial response and stable disease) was observed in 14 patients (48.2%). The median time to tumor progression was 3 months (range 0.7–39) and the median overall survival was 7 months (range 1–39). The 1-year survival rate was 32%. Toxicity was mild. <i>Conclusion:</i> Oxaliplatin is an active agent against biliary tract carcinoma and therefore should be further investigated in combination with other cytotoxic drugs.
Referência(s)